Construction on the workshop is currently underway with plans for it to be fully operational by the end of 2021.
Novasep announced on Nov. 10, 2020 that it is investing EUR 6.5 million (US$7.6 million) to expand capacity for the API manufacturing workshop at its Chasse-sur-Rhône, France, site.
The expanded workshop will include two synthesis reactors (4000L Hastelloy & 1600L glass lined) for low to medium volume APIs that include a high-performance thermal system and a high level of automation, a company press release said. The investment will also include the repositioning of the workshop’s high-pressure hydrogenation reactor (1500L,15bar) to a new area in the space.
Construction on the workshop is currently underway with plans for it to be fully operational by the end of 2021, according to the company press release.
"Upgrading this workshop with the addition of two new reactors will enable us to continue modernizing our Chasse-sur-Rhône site's API manufacturing facilities, whilst improving flexibility and productivity,” said Jean Bléhaut, president of the Synthesis Solutions Business Unit of Novasep, in the press release. "These investments will also reduce our environmental impact by optimizing energy consumption. This is an opportunity for us to respond to social and environmental challenges using technological advances.”
Source: Novasep
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.